Deze website is uitsluitend voorbehouden aan beroepsbeoefenaren in Nederland.
The results from the DUPIREAL real-world study reinforce the efficacy of dupilumab demonstrated in the SINUS-24 and SINUS-52 randomized clinical trials and are consistent with the approved SmPC.1,2,3,4 DUPIREAL is the largest long-term real-world study (n=926) evaluating the effectiveness of dupilumab, including treatment response, disease control and remission, in severe uncontrolled CRSwNP over 2 years.2,3
Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) generally have a high symptom burden and poor health-related quality of life (QoL), often requiring recurring systemic corticosteroid use and repeated sinus surgery.
Efficacy and safety of dupilumab in patients with PN with or without a history of atopic comorbidities
Beyfortus
Atopisch Eczeem bij kinderen
Verborgen ziektelast bij EoE eerder herkennen
Complex immune dysregulation can lead to autoimmunity and inflammation1-6
Patients reported significant quality of life (QoL) challenges related to their ITP1
Low platelet counts are one facet of ITP, but when we look at it from another angle, we see the multiple dimensions of ITP. ITP is a condition of complex immune dysregulation that reduces platelet counts—causing bleeding, bruising, fatigue, and other health-related quality-of-life (HRQoL) issues—while increasing inflammation and the risk of thromboembolic events (TEs).1-5